Is Pinealon the same as Epitalon?

No. Both are Khavinson-class short peptide bioregulators, but they are distinct molecules. Epitalon is the tetrapeptide Ala-Glu-Asp-Gly (AEDG) and has a considerably larger preclinical evidence base, including cell-culture work on telomerase activation. Pinealon (EDR / Glu-Asp-Arg) is a tripeptide studied primarily in Alzheimer's disease models. Despite the name, Pinealon is derived from cortical peptide extracts rather than the pineal gland directly. Evidence attributed to Epithalamin (a raw pineal gland polypeptide extract studied in a Russian longevity trial) should not be conflated with either Epitalon or Pinealon.

Is there any human evidence for Pinealon?

No. As of mid-2026, there are no published controlled human trials for Pinealon (EDR). The published record consists of computational molecular docking studies, in vitro cell experiments, and one rodent Alzheimer's model study — all from a single research group in Saint Petersburg, Russia. No independent replication exists.

How do people use Pinealon and what dose is common?

There is no validated dose. Community reports most commonly describe intranasal administration of approximately 100–200 mcg per dose once daily in cycles of 10–20 days. These figures have no scientific basis and reflect community convention only. This is research-reference information, not dosing guidance.

What is the proposed mechanism?

Khavinson's group proposes that EDR penetrates cell nuclei, binds to DNA promoter regions and histone H1.3, and alters gene expression — including upregulation of antioxidant enzymes (SOD2, GPX1) and suppression of apoptotic pathways. This is supported by computational modeling and in vitro data but has not been confirmed in humans.

Is Pinealon safe and is it WADA-prohibited?

No published human safety data exists. As a tripeptide, it is not expected to be highly toxic, but the absence of toxicology studies means this is an assumption rather than a confirmed fact. Pinealon is not on the current WADA Prohibited List. It is not approved for human use by any regulatory authority. Research use only.

Longevity

Pinealon

Also known as: EDR peptide, Glu-Asp-Arg, EDR tripeptide, Glutamyl-Aspartyl-Arginine

A synthetic Glu-Asp-Arg tripeptide from Vladimir Khavinson's peptide bioregulator class, with proposed neuroprotective and epigenetic-regulatory mechanisms studied almost...

Last updated July 11, 2026

Buy Pinealon

Overview

Pinealon is a synthetic tripeptide with the sequence Glu-Asp-Arg (EDR), developed by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology as part of a broader class of "short peptide bioregulators." Despite the name suggesting a pineal origin, EDR was isolated from bovine cortex peptide extracts rather than the pineal gland directly; its name reflects association with the broader Khavinson bioregulator family rather than strict anatomical sourcing. It is distinct from the more widely discussed Epitalon (AEDG), which is the Khavinson peptide most directly linked to the pineal gland and the most cited for longevity claims. The evidence base for Pinealon (EDR) is sparse and geographically concentrated. Nearly all published studies originate from Khavinson's own group, published predominantly in MDPI open-access journals (Molecules, Pharmaceuticals, International Journal of Molecular Sciences) within the last five years. These are primarily computational molecular docking studies, in vitro cell culture experiments, and rodent models — particularly Alzheimer's disease mouse models. There are no independent replications by other research groups, no human pharmacokinetic studies, no dose-finding trials, and no controlled human efficacy studies of any kind as of mid-2026. Pinealon is sold as a research compound and is discussed in longevity and peptide bioregulator communities alongside Epitalon, Epithalamin, and other Khavinson-class peptides. Claims frequently conflate evidence from the broader Khavinson class (some of which derives from pineal polypeptide extracts, not the synthetic EDR tripeptide) with Pinealon specifically. Any information here is for research and educational reference only, and the evidence ceiling should be clearly understood before interpreting any benefit claims.

How it works

The proposed mechanism is epigenetic in nature, though this is based on computational modeling and in vitro data rather than confirmed human biology. Khavinson's group proposes that short peptides like EDR can penetrate cell nuclei and bind to specific DNA promoter sequences via electrostatic complementarity, altering local chromatin structure. Molecular docking studies suggest EDR interacts with histone H1.3 and nucleotide residues adjacent to gene promoters. Proposed downstream effects include upregulation of antioxidant defense genes (SOD2, GPX1), suppression of pro-apoptotic signaling proteins (caspase-3, p53), and activation of nuclear receptors PPARA/PPARG. EDR also reportedly modulates MAPK/ERK signaling and has been proposed to stimulate serotonin synthesis. In an Alzheimer's disease mouse model (5xFAD), EDR and a related peptide (KED) were reported to prevent dendritic spine loss in the hippocampus. A correction was issued in 2025 for duplicate figure use in that paper, though the authors reported the conclusions remained valid. These mechanisms are plausible but remain provisional and unvalidated in humans.

Researched effects

Preclinical Reduces markers of neuroinflammation and apoptosis in Alzheimer's disease cell and animal models
Preclinical Upregulates antioxidant enzyme expression (SOD2, GPX1) and suppresses caspase-3 in computational and in vitro models
Preclinical Preserves dendritic spine density in hippocampal neurons in a transgenic Alzheimer's mouse model
Preclinical May support cognitive function and neuroprotection with aging (based on preclinical data only)
Anecdotal Reported subjective improvements in cognitive clarity, sleep quality, and mood by community users

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

No established or validated clinical dosing exists. There are no published human pharmacokinetic or dose-finding studies for Pinealon (EDR). No regulatory body has approved Pinealon for any indication.

Community-reported dosing (anecdotal)

Anecdotal and research-reference only; not medical advice. Community discussions (typically online peptide bioregulator forums and Russian-language supplement communities) most commonly describe intranasal administration of reconstituted Pinealon solution — often cited as 100–200 mcg per dose, once daily for cycles of approximately 10–20 days, repeated periodically. Oral capsules are also discussed, though first-pass metabolism of small peptides is a theoretical concern for systemic bioavailability. These figures are completely unvalidated and reflect community convention rather than any evidence base. Significant uncertainty exists about optimal reconstitution, dosing, and route.

Half-life: Not characterized in any published pharmacokinetic study. As a tripeptide with a molecular weight of approximately 417 Da, Pinealon would be expected to have a short serum half-life (minutes to an hour or less, as seen with similar ultrashort peptides), though the claimed mechanism of nuclear entry and gene regulation implies intracellular effects that may persist beyond plasma clearance. Half-life in humans is unknown.
Routes: intranasal, subcutaneous, oral

Safety & side effects

No formal toxicology or human safety studies have been published for Pinealon (EDR). The compound is a tripeptide of naturally occurring amino acids, and Khavinson's broader peptide class is generally described as well tolerated in preclinical contexts with no identified organ toxicity. However, the absence of published safety data is not evidence of safety; human responses to pharmacologically active peptides that interact with gene regulation machinery are not predictable from structure alone. Long-term safety is entirely uncharacterized. Product quality of research-grade Pinealon is an additional real-world concern: purity, sterility, and concentration accuracy in unregulated material are not guaranteed. Pinealon is not WADA-prohibited as of current published prohibited lists. It is not approved for human use by any regulatory authority. Research use only.

Research summary

The published evidence for Pinealon (EDR) is limited in both quantity and independence. The compound appears in PubMed through a cluster of papers from Khavinson's Saint Petersburg group, primarily from 2020 onward. The mechanistic narrative — short peptides as epigenetic regulators through DNA promoter binding — is internally consistent and draws on a broader theoretical framework that Khavinson has developed over decades. The in vitro and rodent-model data show effects on Alzheimer's-related molecular pathways, and computational docking studies identify plausible binding sites on histones and DNA. However, several critical gaps undermine confidence. First, all published research comes from one group with no independent replication by other labs. Second, the proposed mechanism (peptide binding to nuclear DNA altering transcription) is novel enough to warrant extensive validation before clinical extrapolation. Third, a 2025 correction for the primary Alzheimer's mouse model paper due to duplicate figure use raises questions about rigor, even if conclusions were upheld. Fourth, the clinical longevity evidence often cited in community discussions derives from Epithalamin (a raw pineal polypeptide extract studied in a six-year Russian clinical trial reporting reduced mortality) — this is not evidence for the synthetic EDR tripeptide. Fairly assessed: Pinealon is a plausible but unproven neuroprotective research compound. Its evidence base is thin, non-independent, and entirely preclinical. Any benefit claims must be treated as speculative pending independent replication and human studies.

FAQ

Is Pinealon the same as Epitalon?: No. Both are Khavinson-class short peptide bioregulators, but they are distinct molecules. Epitalon is the tetrapeptide Ala-Glu-Asp-Gly (AEDG) and has a considerably larger preclinical evidence base, including cell-culture work on telomerase activation. Pinealon (EDR / Glu-Asp-Arg) is a tripeptide studied primarily in Alzheimer's disease models. Despite the name, Pinealon is derived from cortical peptide extracts rather than the pineal gland directly. Evidence attributed to Epithalamin (a raw pineal gland polypeptide extract studied in a Russian longevity trial) should not be conflated with either Epitalon or Pinealon.
Is there any human evidence for Pinealon?: No. As of mid-2026, there are no published controlled human trials for Pinealon (EDR). The published record consists of computational molecular docking studies, in vitro cell experiments, and one rodent Alzheimer's model study — all from a single research group in Saint Petersburg, Russia. No independent replication exists.
How do people use Pinealon and what dose is common?: There is no validated dose. Community reports most commonly describe intranasal administration of approximately 100–200 mcg per dose once daily in cycles of 10–20 days. These figures have no scientific basis and reflect community convention only. This is research-reference information, not dosing guidance.
What is the proposed mechanism?: Khavinson's group proposes that EDR penetrates cell nuclei, binds to DNA promoter regions and histone H1.3, and alters gene expression — including upregulation of antioxidant enzymes (SOD2, GPX1) and suppression of apoptotic pathways. This is supported by computational modeling and in vitro data but has not been confirmed in humans.
Is Pinealon safe and is it WADA-prohibited?: No published human safety data exists. As a tripeptide, it is not expected to be highly toxic, but the absence of toxicology studies means this is an assumption rather than a confirmed fact. Pinealon is not on the current WADA Prohibited List. It is not approved for human use by any regulatory authority. Research use only.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.